Merck Research Laboratories

Latest articles

28d
Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)advanced gastric or GEJ cancer, helping to address a recognized treatment gap,”
Business Wire / Posted 28 days ago
advanced gastric or GEJ cancer, helping to address a recognized treatment gap,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “This approval marks another milestone – the tenth new indication for KEYTRUDA in just three... Read more
5 related articles

In this news